Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug

Clinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a Crowd

BioWorldBiggest gainers and losers for May 4-8, 2026

Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan

BioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

FDA News ReleasesFDA Advances Drug Repurposing to Address Unmet Medical Needs

Endpoints NewsBraveheart Bio's Hengrui-licensed cardiac drug scores second clinical win

BioPharma DiveBiotech layoffs are easing, but is the worst over?

FierceBiotechNovo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech

BioWorldShanghai Jeyou Pharmaceutical patents LGALS3 inhibitors